Metabolic basis of high density lipoproteins and apolipoprotein AI increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery …
JR Schaefer, H Schweer, K Ikewaki, H Stracke… - Atherosclerosis, 1999 - Elsevier
HMG-CoA reductase inhibitors, such as pravastatin, are widely used as lipid lowering drugs
in hypercholesterolemia. Pravastatin does not only reduce the atherogenic low density
lipoprotein (LDL)-cholesterol, but is also increasing high density lipoprotein (HDL)-
cholesterol. However, the mechanism leading to an increase of HDL are unclear. Therefore,
the effects of pravastatin on the in vivo kinetics of apolipoprotein (apo) AI were studied in six
normolipidemic subjects and in a patient with coronary artery disease (CAD) utilizing stable …
in hypercholesterolemia. Pravastatin does not only reduce the atherogenic low density
lipoprotein (LDL)-cholesterol, but is also increasing high density lipoprotein (HDL)-
cholesterol. However, the mechanism leading to an increase of HDL are unclear. Therefore,
the effects of pravastatin on the in vivo kinetics of apolipoprotein (apo) AI were studied in six
normolipidemic subjects and in a patient with coronary artery disease (CAD) utilizing stable …